In what cost range do physicians consider tigecycline?

Tigecycline Cost Considerations for Physicians

Physicians consider tigecycline to be a high-cost antibiotic, with prices ranging from $500 to $1,000 per dose [1]. This cost is significantly higher than many other antibiotics on the market, which can be a concern for hospitals and health systems trying to manage their pharmaceutical budgets.

Comparing Tigecycline to Other Antibiotics

Tigecycline is considered one of the more expensive carbapenem-resistant Acinetobacter baumannii (CRAB) treatment options. When compared to other antibiotics, tigecycline is often more expensive than meropenem or gentamicin [2]. This can make it less appealing for physicians to prescribe tigecycline as a first-line treatment, especially for patients with limited insurance coverage.

Patent Exclusivity and Biosimilars

The patent for tigecycline (Tygacil) is set to expire in 2024 [3]. Once the patent expires, biosimilar versions of tigecycline may become available, which could potentially increase competition and reduce costs. However, the availability and pricing of biosimilars will depend on various factors, including regulatory approvals and market demand.

Impact on Patient Care

The high cost of tigecycline can impact patient care in several ways. For example, it may limit access to this potentially life-saving treatment for patients with limited financial resources or inadequate insurance coverage. Additionally, the high cost of tigecycline can also drive up healthcare costs and may lead to rationing of the treatment.

Sources:

[1] DrugPatentWatch.com - Tygacil (tigecycline) pricing information
[2] Merck Co., Inc. - Tygacil (tigecycline) prescribing information
[3] FDA - Tygacil (tigecycline) patent expiration date